ReviewInsights into imaging2022
Multimodal molecular imaging evaluation for early diagnosis and prognosis of cholangiocarcinoma.
Review in Insights into imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Listening to Immunotherapy - Ultrasound and Photoacoustic Imaging Strategies to Guide and Enhance Cancer Treatments.Molecular imaging and biology · 2026Review
- Confocal laser endomicroscopy improves diagnosis of cholangiocarcinoma: a case report and review.Open life sciences · 2026Article
- Intrahepatic Cholangiocarcinoma Masquerading as Liver Abscess: A Case Report With Multimodal Imaging.Clinical case reports · 2025Article
- Optical imaging guidance in oncologic surgery and interventional oncology.Pharmacological research · 2025Review
- Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatment.World journal of surgical oncology · 2024Article
- Intraductal magnetic resonance imaging of cholangiocarcinoma - a practical possibility.Frontiers in oncology · 2024Article
- Ubiquitin-conjugating enzyme E2C (UBE2C) is a prognostic indicator for cholangiocarcinoma.European journal of medical research · 2023Article
- Advances in optical molecular imaging for neural visualization.Frontiers in bioengineering and biotechnology · 2023Review
- Surgical Aspects of Intrahepatic Cholangiocarcinoma.Cancers · 2022Review
- Article
- Current Status ofDiagnostics (Basel, Switzerland) · 2022Review
- A review of current evidence about lncRNA MEG3: A tumor suppressor in multiple cancers.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cholangiocarcinoma (CCA) is an aggressive and lethal malignancy with limited therapeutic options. Despite recent advances in diagnostic imaging for CCA, the early diagnosis of CCA and evaluation of tumor invasion into the bile duct and its surrounding tissues remain challenging. Most patients with CCA are diagnosed at an advanced stage, at which treatment options are limited. Molecular imaging is a promising diagnostic method for noninvasive imaging of biological events at the cellular and molecular level in vivo. Molecular imaging plays a key role in the early diagnosis, staging, and treatment-related evaluation and management of cancer. This review will describe different methods for molecular imaging of CCA, including nuclear medicine, magnetic resonance imaging, optical imaging, and multimodal imaging. The main challenges and future directions in this field are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.